IRISH MEDICINES BOARD ACT 1995

EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007

(S.I. No. 786 of 2007)

VPA: **10996/017/001**
Case No: 7004980

The Irish Medicines Board in exercise of the powers conferred on it by Animal Remedies (No. 2) Regulations (S.I. No. 786 of 2007) hereby grants to:

Intervet Ireland Limited

Magna Drive, **Magna Business Park**, **Dublin 24**, **Ireland**

an authorisation, subject to the provisions of the said Regulations and the general conditions of the attached authorisation, in respect of the Veterinary Medicinal Product:

Oestradiol Benzoate 5 mg/ml solution for injection

The particulars of which are set out in Part 1 and Part 2 of the said Schedule. The authorisation is also subject to any special conditions as may be specified in the said Schedule.

The authorisation,unless revoked, shall continue in force from **18/08/2008**.

Signed on behalf of the Irish Medicines Board

_____

A person authorised in that behalf by the said Board.

(NOTE: This authorisation replaces any previous authorisation in respect of this product which is now null and void.)

Part II

Summary of Product Characteristics

1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Oestradiol Benzoate 5 mg/ml solution for injection

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of product contains:	
Active substance	
Estradiol benzoate	5 mg
Excipients	
Benzyl alcohol	104 mg

For a full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Solution for injection.

A clear, oily solution.

4 CLINICAL PARTICULARS

4.1 Target Species

Female animals: mares and fillies declared as not intended for human consumption
cows and bitches
Male animal: dogs

4.2 Indications for use, specifying the target species

Cows:
- Treatment of mummification
- Treatment of pyometra

Mares/fillies as not intended for human consumption
- Oestrus induction

Bitches:
- Inducing signs of heat
- Mesalliance
- Urinary incontinence

Dogs:
- Treatment of anal adenomata and prostatic hyperplasia
- Treatment of excessive libido

4.3 Contraindications

Do not use this product in cats.
Do not use this product in known cases of hypersensitivity to the active ingredients.

4.4 Special warnings for each target species

Large doses of oestrogens in the dog have been associated with blood dyscrasias and pathological changes in the uterus. It is therefore important to follow the dosage recommendations given above.
This product contains benzyl alcohol, which has been documented to cause adverse reactions in neonates. For this reason, the product should not be used in very young animals.

4.5 Special precautions for use

Special precautions for use in animals
None

Special precautions to be taken by the person administering the veterinary medicinal product to animals
None

4.6 Adverse reactions (frequency and seriousness)

Large doses of oestrogens in the dog have been associated with blood dyscracias and pathological changes in the uterus. It is therefore important to follow the dosage recommendations given below.

4.7 Use during pregnancy, lactation or lay

No special precautions necessary.

4.8 Interaction with other medicinal products and other forms of interaction

None known.

4.9 Amounts to be administered and administration route

All indications in the cow and mare.
Dosage: 3 mg/500 kg
Treatment may be repeated at 7 day intervals if required.

Mesalliance in the bitch:
Dosage: 0.3 mg/kg to a maximum of 10 mg.
A single treatment should be given between 24 hours and 4 days after the mating.

Other indications in dogs (anal adenomata, excess libido, prostate hyperplasia) and bitches (hypogonadal obesity, urinary incontinence in spayed animals):
Dosage: 0.1 mg/kg
Treatment may be repeated daily until a response is seen (maximum 7 days) and then at 7 day intervals.

Administer by intramuscular or subcutaneous injection, observing the usual aseptic precautions. Use a dry, sterile needle and syringe.

Swab the septum before removing each dose.

As with all physiological hormone therapies, there can be considerable variation in response to treatment. The above dosages may need to be adjusted according to clinical response.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No special treatment or antidote recommended.

4.11 Withdrawal Period(s)

Cattle:
Meat: 5 days
Milk: Zero days

Treated horses must never be slaughtered for human consumption.

5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic Group: Estrogens, Estradiol.
ATCvet Code: QG03CA03.

5.1 Pharmacodynamic properties

In the female, oestrogens are responsible for initiating oestrus and the changes in the reproductive system in preparation for impregnation and fertilisation, prior to the further developments promoted by progesterone. Duct development in the mammary gland also results from oestrogen action.

In the male, oestrogens exert anabolic and similar non-specific steroid activity in addition to antagonising some of the virilising actions of the androgens.

5.2 Pharmacokinetic properties

Following administration of oestradiol benzoate to dogs, C max is reached within 3-4h and elimination half life ranges between 5 and 9 hours. After absorption, oestradiol benzoate is hydrolyzed to oestradiol by plasma esterases. Further metabolism by the liver results in the formation of conjugates (mainly glucuronides). The main excretory pathways in dogs involve the bile and the faeces.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzyl alcohol
Arachis oil

6.2 Incompatibilities

Do not dilute or mix with other compounds.

6.3 Shelf-life

Shelf-life of the veterinary medicinal product as packaged for sale: 5 years.
Shelf-life after withdrawal of the first dose: 28 days.

6.4 Special precautions for storage

Do not store above 25^{o}C. Protect from light. At a low temperature the product may become viscous. Warming the vial in the hand will return the contents to the normal state.

6.5 Nature and composition of immediate packaging

Clear, Type I (Ph.Eur) glass vials of 10 ml closed with rubber bromobutyl bung with aluminium overseal.. Each vials contains 10 ml of a clear, sterile, oily solution.

6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials

Unused product or waste materials should be disposed of in accordance with current practice for pharmaceutical waste under national waste disposal regulations.

7 MARKETING AUTHORISATION HOLDER

INTERVET IRELAND Ltd.
Magna Drive
Magna Business Park
Citywest Road
DUBLIN 24

8 MARKETING AUTHORISATION NUMBER(S)

VPA 10996/017/001

9 DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

1st October 2002

10 DATE OF REVISION OF THE TEXT

18th August 2008